MedTrace Logo

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

NCT00018902 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2014-03-12

No results posted yet for this study

Summary

The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.

Conditions

Interventions

DRUG

Fluoxetine

Standard anti-depressant treatment with the SSRI fluoxetine

DRUG

Venlafaxine

Standard antidepressant treatment with the non-SSRI medication venlafaxine

BEHAVIORAL

Cognitive Behavioral Therapy (CBT)

CBT addresses maladaptive beliefs in order to encourage behavioral change

DRUG

Citalopram

Standard anti-depressant treatment with the SSRI fluoxetine

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • David A. Brent, MD · Western Psychiatric Institute and Clinic (Data Coordinating Center)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00018902 on ClinicalTrials.gov